Daratumumab, lenalidomide, and dexamethasone for multiple myeloma


Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine [Internet]. 2016;375(14):1319 - 1331.


BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: At a median follow-up of 13.5 months in a protocol-specified interim analysis, 169 events of disease progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% confidence interval [CI], 0.27 to 0.52; P<0.001 by stratified log-rank test). The Kaplan- Meier rate of progression-free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group. A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%, P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%, P<0.001). In the daratumumab group, 22.4% of the patients had results below the threshold for minimal residual disease (1 tumor cell per 105 white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. Copyright © 2016 Massachusetts Medical Society. All rights reserved.


Cited By :13Export Date: 18 February 2017References: Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Improved survival in multiple myeloma and the impact of novel therapies (2008) Blood, 111, pp. 2516-2520;Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients (2014) Leukemia, 28, pp. 1122-1128; Richardson, P.G., Hideshima, T., Mitsiades, C., Anderson, K.C., The emerging role of novel therapies for the treatment of relapsed myeloma (2007) J Natl Compr Canc Netw, 5, pp. 149-162; Moreau, P., Touzeau, C., Multiple myeloma: From front-line to relapsed therapies (2015) Am Soc Clin Oncol Educ Book, 35, pp. e504-e511; Kumar, S., Paiva, B., Anderson, K.C., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (2016) Lancet Oncol, 17 (8), pp. e328-e346; Martinez-Lopez, J., Lahuerta, J.J., Pepin, F., Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma (2014) Blood, 123, pp. 3073-3079; Lonial, S., Anderson, K.C., Association of response endpoints with survival outcomes in multiple myeloma (2014) Leukemia, 28, pp. 258-268; De Weers, M., Tai, Y.T., Van Der Veer, M.S., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors (2011) J Immunol, 186, pp. 1840-1848; Lonial, S., Weiss, B.M., Usmani, S.Z., Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial (2016) Lancet, 387, pp. 1551-1560; Lokhorst, H.M., Plesner, T., Laubach, J.P., Targeting CD38 with daratumumab monotherapy in multiple myeloma (2015) N Engl J Med, 373, pp. 1207-1219; McKeage, K., Daratumumab: First global approval (2016) Drugs, 76, pp. 275-281; (2016) EPAR Summary for the Public: Darzalex (Daratumumab), , http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_..., London: European Medicines Agency; Overdijk, M.B., Jansen, J.H., Nederend, M., The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptormediated cross-linking (2016) J Immunol, 197, pp. 807-813; Overdijk, M.B., Verploegen, S., Bogels, M., Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma (2015) MAbs, 7, pp. 311-321; Lammerts Van Bueren, J., Jakobs, D., Kaldenhoven, N., Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 The 56th Annual Meeting and Exposition of the American Society of Hematology, , Presented at, San Francisco, December 6-9, 2014. abstract; Laubach, J.P., Richardson, P.G., CD38- targeted immunochemotherapy in refractory multiple myeloma: A new horizon (2015) Clin Cancer Res, 21, pp. 2660-2662; Krejcik, J., Casneuf, T., Nijhof, I.S., Daratumumab depletes CD38+ immuneregulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma (2016) Blood, , May 24 (Epub ahead of print); Palumbo, A., Chanan-Khan, A., Weisel, K., Daratumumab, bortezomib and dexamethasone for multiple myeloma (2016) N Engl J Med, 375, pp. 754-766; Plesner, T., Arkenau, H.T., Gimsing, P., Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma (2016) Blood, , August 16 (Epub ahead of print); Durie, B.G.M., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; Rajkumar, S.V., Harousseau, J.L., Durie, B., Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1 (2011) Blood, 117, pp. 4691-4695; Durie, B.G., Miguel, J.F., Blade, J., Rajkumar, S.V., Clarification of the definition of complete response in multiple myeloma (2015) Leukemia, 29, pp. 2416-2417; McCudden, C., Axel, A.E., Slaets, D., Monitoring multiple myeloma patients treated with daratumumab: Teasing out monoclonal antibody interference (2016) Clin Chem Lab Med, 54, pp. 1095-1104; DeMets, D.L., Lan, G., The alpha spending function approach to interim data analyses (1995) Cancer Treat Res, 75, pp. 1-27; Lan, K.K.G., DeMets, D.L., Discrete sequential boundaries for clinical trials (1983) Biometrika, 70, pp. 659-663; Chapuy, C.I., Nicholson, R.T., Aguad, M.D., Resolving the daratumumab interference with blood compatibility testing (2015) Transfusion, 55, pp. 1545-1554; Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372, pp. 142-152; Moreau, P., Masszi, T., Grzasko, N., Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma (2016) N Engl J Med, 374, pp. 1621-1634; Zonder, J.A., Mohrbacher, A.F., Singhal, S., A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma (2012) Blood, 120, pp. 552-559; Lonial, S., Dimopoulos, M., Palumbo, A., Elotuzumab therapy for relapsed or refractory multiple myeloma (2015) N Engl J Med, 373, pp. 621-631; Dimopoulos, M., Spencer, A., Attal, M., Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma (2007) N Engl J Med, 357, pp. 2123-2132; Chari, A., Lonial, S., Suvannasankha, A., Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma (MM) (2015) Blood, 126, p. 0508. , abstract